Kelly Shi: Yes, so I meant for the Phase 2, the potentially pivotal trial. Do you plan to have another data update this year? And at the moment, how many sites have been activated, study site?
Philippe Martin: I don’t believe we anticipate to have data update. This is a registration study. Patients are being randomized. So we’re not planning on giving data update, but will certainly provide enrollment updates. And what was good with this study is that we were able to leverage all the UPS, all the soft tissue sarcoma and bone sarcoma sites we had for initiated for Phase 2, part 1. So these sites are being transitioned to the second part of this phase, which is about 40 sites altogether in the US, Hong Kong and Taiwan.
Operator: Our next question comes from the line of Tony Buter of EF Hutton.
Tony Buter: Yes, thanks very much. So a question around the CTLA-4 program in clintrials.gov, and one would anticipate clearly there’s been dosing for a variety of tumors. So the first question is, has enrollment been, has it included and have the patients have all of the tumors which are listed on clintrials.gov been dosed in your early dosing schedule? And importantly, and if not, that’s fine, but has it been skewed to one particular tumor or another? That’s question one, number two is in the same program, what actually could you, enunciate which parameters that you’re simply looking for? Is it just simply DLT? And then when do you think that you will get to an appropriate dose that you can then start looking at efficacy? Will that be within this first half? Do you think it takes the entire year? Thanks very much.
Jay Short: I’m going to split this with Philly. But so I think that when you’re at when 1 mg/kg, you’re in an approved dose race, especially in combination with 3 mg/kg PD-1. So we passed that cohort. We just passed the 3 mg/kg in combination with 3 mg/kg of PD-1. So there’s another cohort that’s in that efficacy range. We’re enrolling now for the 5 mg/kg in combination with 3mg/kg PD-1. So everything on out in the last two cohorts have the potential for looking at efficacy, and of course, we will look at that. But I think so this study in general, I think, is on track to be done in times such that we can actually kick off or initiate our Phase 2 trial in the BA3071 with the CTLA-4. So it’s on a very good pace, and we’re thrilled to see the data is coming in the way we hoped it would so far. But there were some other questions about the tumor types and maybe even a comment or two regarding efficacy readouts and so forth that maybe would be better for Philip to answer.
Philippe Martin: Yes. Thanks, Jay. So I think the only tumor type we have not enrolled is HCC at this point. All the other tumor types have been enrolled. We’re seeing quite a bit of activity and quite a bit of patients coming to our study in all the tumor types that we have listed. And so, as Jay mentioned, we’ve really surpassed efficacy threshold levels that we were expected, Ipilimumab is approved at 1 mg/kg in combination with nivolumab at 3 mg/kg in certain indication, 3 mg Ipilimumab plus 1 mg nivolumab other indications. So we have reached level with these cohorts where we certainly expect to see efficacy, but we’ll also be looking at other markers of efficacy, such as CTDNA, tumor burden, so on and so forth, to also help us make a decision on which dose to take forward into the Phase 2 part of the study.
Operator: Our next question comes from the line of Arthur He with H.C. Wainwright.
